XpresSpa Earnings Reports

XWELL, Inc. reported a revenue of $8.4 million for the third quarter of 2024, compared to $7.5 million for the 2023 third quarter. The operating loss was approximately $4.8 million, compared with an operating loss of approximately $12.1 million for the 2023 third quarter. Net loss attributable to XWELL was approximately $4.8 million, compared to approximately $11.5 million for the 2023 third quarter.

XWELL, Inc. reported a revenue increase to $9.3 million compared to $8.2 million in the second quarter of 2023. The company also reduced its operating loss to $1.9 million from $4.7 million and net loss to $2.0 million from $5.7 million year-over-year. The company continues to focus on strategic growth and cost reduction.

XWELL reported a 24% increase in revenue compared to Q1 2023, alongside a 26% reduction in operating expenses and a 62% decrease in operating loss. The company is focused on long-term strategic priorities, including improving results, reaching profitability, and expanding its wellness portfolio.

XWELL, Inc. reported fiscal year 2023 results, highlighting revenue of $30.1 million, driven by XpresSpa, Treat locations, and XpresTest. The company is focused on expanding wellness services, growing internationally, and extending its reach beyond airports.

XWELL, Inc. reported a decrease in total revenue for Q3 2023, primarily due to reduced COVID-19 testing revenue, offset by growth in airport spa revenue and the acquisition of Naples Wax Center. The company is focused on operational efficiency and expanding its wellness portfolio, including international growth and exploring other transportation hubs.

XWELL reported a decrease in revenue due to the closure of XpresCheck locations, offset by cost-saving initiatives that led to lower operating expenses. The company is focused on improving operating performance and investing in growth.

XWELL, Inc. reported a total revenue of $7.1 million for the first quarter ended March 31, 2023, compared to $24.0 million in the prior year first quarter. The company's net loss attributable to common shareholders was $5.5 million for the first quarter of 2023, compared to a net loss of $4.3 million in the first quarter of 2022. As of March 31, 2023, the Company had cash and cash equivalents of approximately $9.9 million and marketable securities of approximately $25.2 million.

XWELL, Inc. reported its fiscal year 2022 results, highlighting strategic progress, including evolving the organization, optimizing efficiencies, and focusing on long-term growth. The company is positioning itself for improved performance in 2023 by leveraging recent progress in its spa business, retail growth initiatives, biosurveillance expansion, and potential acquisitions.

XWELL, Inc. reported a total revenue of $10.7 million for the third quarter of 2022, compared to $26.8 million in the corresponding period in 2021. The company experienced a net loss attributable to common shareholders of $7.2 million, compared to a net income of $5.6 million in the prior year third quarter. Despite the losses, the company is focused on strategic objectives, international expansion, retail strategy implementation, and cost reduction to achieve profitability in 2023.

XpresSpa Group reported a revenue increase to $13.6 million compared to $9.1 million in the corresponding period in 2021. The company's net loss attributable to common shareholders was $7.9 million, compared to $4.5 million in the prior year second quarter. XpresCheck was awarded a new CDC contract valued up to $61 million.

XpresSpa Group reported a total revenue of $24.0 million for Q1 2022, compared to $8.5 million in the corresponding period in 2021. The company had a cash balance of $83.0 million and no long-term debt. They also repurchased $11.1 million of shares during the quarter.

XpresSpa Group reported record financial results for Q4 2021, with revenue reaching $29.4 million and net income at $3.3 million. The company generated significant operating cash flow and actively repurchased shares, ending the year with a strong liquidity position of $105.5 million in unrestricted cash.

XpresSpa Group reported record quarterly revenue of $26.8 million and net income of $5.6 million in Q3 2021, driven by strong performance of XpresCheck locations.

XpresSpa Group reported $9.1 million in total revenue, including $8.7 million from XpresCheck, and significantly reduced its Adjusted EBITDA loss and net loss compared to the previous year. The company is expanding its services with the Treat brand and re-opening legacy XpresSpa locations.

XpresSpa Group reported a revenue of $8.5 million for Q1 2021, primarily driven by XpresCheck, and narrowed its net loss to $0.8 million. The company's strong liquidity position includes a cash balance of $103 million, and it is introducing Treat, a new travel health and wellness brand.

XpresSpa Group's Q4 2020 revenue decreased due to COVID-19's impact on spa operations. The company focused on XpresCheck wellness centers, which showed promising patient testing volumes and revenue per patient. Despite not recognizing revenue from XpresCheck in Q4 2020, the company anticipates revenue recognition in 2021. They are also developing a new travel health and wellness brand.

XpresSpa Group reported a decrease in revenue for Q3 2020 due to temporary closures of spa locations, offset by revenue from strategic spa partners. The company is focusing on expanding its XpresCheck wellness centers and developing a travel health and wellness brand.

XpresSpa Group announced its Q2 2020 financial results, highlighting the launch of XpresCheck COVID-19 testing facilities at JFK and Newark airports. The company temporarily closed all global spa locations due to COVID-19 restrictions and is focusing on expanding its health and wellness services through XpresCheck.